He Jiankui spent three years in prison after creating gene-edited babies. Now back at work, he sees a greater opening for ...
The Chosun Ilbo on MSN
Obesity drugs, M&A revive US biotech investment
U.S. biotech firm Dyne Therapeutics develops treatments for rare neuromuscular diseases, including Duchenne muscular ...
Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with ...
Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...
The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026 ...
Insmed's CEO said months ago that the commercial opportunity for the biotech's newly approved lung disease drug was "huge." ...
Several Bay Area biotech companies announced big funding rounds totaling hundreds of millions of dollars just before the ...
Learn how spectroscopy facilitates non-invasive, real-time bio-monitoring, enhancing decision-making in healthcare, ...
Eikon Therapeutics is planning to become the second biotech to go public in 2026, in another sign that the public markets are ...
The University of Pennsylvania, biotech firm BioNTech, and Osage University Partners, a venture capital firm in Bala Cynwyd, ...
From lab space and coffee bars to jobs and long-term returns, mid-tier life sciences hubs may be better positioned than the biggest biotech boomtowns.
CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback